戻る
Century Therapeutics Inc (IPSC)価格
IPSC 株価推移チャート
IPSC 財務
Century Therapeutics Inc
$1.75
0%
$0
終値： Feb 13, 16:00:00 GMT-5
$1.75
0%
$0
アフターマーケット：Feb 13, 20:00:00 GMT-5
収入
貸借対照表
現金の流れ
年次
四半期
IPSC 収入
金額は百万米ドル単位。会計年度は2月から1月まで。
Follow-Up Questions
Century Therapeutics Incの主要な財務諸表は何ですか？
IPSCの主要な財務比率は何ですか？
Century Therapeutics Incの収益はセグメントまたは地域別にどのように分けられていますか？
Century Therapeutics Incは収益を上げていますか？
Century Therapeutics Incに負債はありますか？
Century Therapeutics Incの発行済株式数は何株ですか？
主要データ
前終値
$1.75
始値
$1.78
当日レンジ
$1.75 - $1.86
52週レンジ
$0.342 - $2.71
取引高
610.6K
平均取引高
1.8M
1株当たり利益(TTM)
-0.31
配当利回り
--
時価総額
$152.7M
IPSCとは何ですか？
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 140 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The firm has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.